Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned an average rating of “Hold” from the twenty-three brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $104.4211.

Several analysts recently issued reports on ZBH shares. Canaccord Genuity Group increased their target price on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Citigroup lowered their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Royal Bank Of Canada boosted their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th.

Zimmer Biomet Trading Down 2.0%

Shares of Zimmer Biomet stock opened at $99.40 on Friday. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $106.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $18.96 billion, a P/E ratio of 24.19, a P/E/G ratio of 2.76 and a beta of 0.45. The company has a fifty day moving average of $93.63 and a 200 day moving average of $91.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period last year, the firm earned $2.07 earnings per share. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently made changes to their positions in the business. DV Equities LLC purchased a new position in Zimmer Biomet in the fourth quarter worth about $25,000. Tacita Capital Inc bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $26,000. Ancora Advisors LLC bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $29,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet during the 4th quarter valued at $30,000. Finally, Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet during the 4th quarter valued at $31,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.